GHRS

GH Research PLC

Nasdaq· Pharmaceutical Preparations· Inc. L2· CIK 0001855129 Biotech & Drug Discovery

$19.13 +1.06 (+5.87%)

Oct 26 4:00 PM ET · prev $18.07

Market cap

$1.3B

Small cap

Consensus

Buy

94% Buy or better · 17 analysts

Median target

$40.00

+109% · range $38.00–65.00

Next earnings

Nov 5

in 10 days · EPS est. −$0.30

1 year

+33.6%

from $14.31 · Oct 27

30 days

−18.3%

from $23.42

52-week range

$12.48–30.64

−38% from high · low Dec 15

Avg volume 20D

352.1K

Sep 29 spike 1.13M

Short interest

1.76M

≈2.6% of shares · −34.8%

Days to cover

5.0

at average volume

Insider net

no open-market trades · 12 mo

New fund stakes

Q2 2026 13F · 1 exit

SecBot read BULLISH 3 reports · 90 days

Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 3/3 ·Next Earnings date, Nov 5, 2026

Strongest BULLISH GH Research reported Q2 2026 financial results with a net loss of $15.1 million ($0.23 per share), widening…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Mar 5 GH Research reported financial results for 2025, highlighted by a st…
R Mar 25 GH Research PLC announced the publication of Phase 2b trial results…
E Mar 25 FDA: GH Research Announces Publication of Phase 2b Results for…
R May 14 GH Research PLC filed a 424B5 prospectus supplement to register an a…
A Jul 27 Wells Fargo initiates
X Jul 31 Short interest jumps 30.0% to 2.53M
R Aug 6 GH Research reported Q2 2026 financial results with a net loss of $1…
X Sep 30 Short interest falls 34.8% to 1.76M

Signal stack

Where each data set points today.

InsidersNO TRADES

No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
InstitutionsBULLISH

Q2 2026: 9 added (0 new), 3 trimmed or exited.
AnalystsBULLISH

16 of 17 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$0.361 → −$0.302 over 90 days. 6 up, 1 down in 30 days.
Short sellersCOVERING

Short interest −34.8% to 1.76M shares. 5.0 days to cover, ≈2.6% of shares.
TrendDOWNTREND

23% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exit

Fund	Move	Shares	Value
MILLENNIUM MANAGEMENT LLC	TRIM	323,399	$8.7M
Trexquant Investment LP	DOUBLED	153,767	$4.1M
GOLDMAN SACHS GROUP INC	DOUBLED	148,673	$4.0M
CITADEL ADVISORS LLC	ADD	85,952	$2.3M
MORGAN STANLEY	DOUBLED	52,218	$1.4M
MARSHALL WACE, LLP	TRIM	46,697	$1.3M
TUDOR INVESTMENT CORP ET AL	ADD	34,278	$921.4K
BARCLAYS PLC	ADD	5,977	$160.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts

Buy 94% rate it Buy or better

Strong Buy5Buy11Hold1Sell0Strong Sell0

12-month targets · 9 analysts

$19.13 $38.00 $40.00 $65.00

Price is below the lowest target. Median implies +109%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 7, 2026	Guggenheim MAINTAIN	MAINTAIN	Buy
Aug 7, 2026	Cantor Fitzgerald MAINTAIN	MAINTAIN	Overweight
Aug 6, 2026	Needham MAINTAIN	MAINTAIN	Buy
Jul 27, 2026	Wells Fargo INITIATE	INITIATE	Overweight
May 19, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
May 15, 2026	Cantor Fitzgerald MAINTAIN	MAINTAIN	Overweight

Insider ledger

Form 4

open-market buys or sells · 12 mo

Date	Insider	Type	Value
Sep 8, 2026	Schonharting Florian Director	AWARD	2,303 sh
Aug 11, 2026	Hanley Dermot John Director	AWARD	2,202 sh
Aug 11, 2026	Moore Duncan Director	AWARD	2,202 sh
Aug 11, 2026	Forer Michael Director	AWARD	2,202 sh
Aug 11, 2026	Forer Michael Director	AWARD	100,000 sh

Earnings setup

Estimates

Nov 5

reports in 10 days

−$0.30

EPS estimate, this quarter

+16%

estimate change, 90 days

6↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.361

90d

−$0.302

60d

−$0.302

30d

−$0.302

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.30	-$0.43–-$0.22	+0.0%	$0.00
Next Q	-$0.35	-$0.49–-$0.23	+0.0%	$0.00
Current FY	-$1.17	-$1.41–-$0.98	+0.0%	$0.00
Next FY	-$1.85	-$2.67–-$1.31	+0.0%	$0.00